眼内甲氨蝶呤治疗上皮性下生长:多中心病例系列的长期结局
这项回顾性多中心病例系列纳入10只眼(9例患者),评估眼内甲氨蝶呤(MTX)治疗片状上皮性下生长(EDG)的长期结局。多数患者接受400微米/0.1毫升MTX注射,起始频率为每周两次或每周一次,平均注射16±13次,随访54±36个月。7只眼实现EDG根除,2只眼临床缓解后复发,1只眼治疗失败;8例患者出现表面上皮病变并用于滴定MTX治疗,6例患者出现内皮衰竭。
要点
- 眼内MTX治疗片状EDG,10只眼中7只实现根除,2只缓解后复发,1只治疗失败。
- 多数患者MTX注射方案为400微米/0.1毫升,起始每周两次或每周一次,平均注射16±13次。
- 8例患者出现表面上皮病变并用于滴定MTX治疗,6例患者出现内皮衰竭。
核心结论
- 眼内MTX可用于在手术不可行的情况下有效实现EDG根除。
- 原文认为仍需要进一步推荐来指导治疗。
研究设计与样本
- 回顾性、多中心病例系列,纳入10只眼(9例患者)接受眼内MTX治疗片状EDG。
主要发现
- 所有病例均与眼内手术相关。
- 多数患者接受400微米/0.1毫升MTX注射,起始频率为每周两次或每周一次。
- 每只眼平均注射次数为16±13次,随访时间为54±36个月(范围7至120个月)。
- 7只眼实现EDG根除,其中1只眼需要第二个MTX疗程才实现根除;2只眼观察到临床缓解但复发。
- 1只眼治疗失败,尽管接受了8次每周注射,治疗减缓但未阻止EDG进展;该患者后来因随访困难要求停止治疗。
临床怎么用
- 原文结论认为眼内MTX可用于在手术不可行的情况下有效实现EDG根除。
- 原文结论认为仍需要进一步推荐来指导治疗。
局限性
- 原文结论认为仍需要进一步推荐来指导治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Sheet-like type of epithelial downgrowth (EDG) is not easily amenable to surgical excision. We describe long-term outcomes in patients with EDG treated with intraocular methotrexate (MTX). METHODS: This is a retrospective, multicentric case series including 10 eyes (nine patients) treated with intraocular MTX for sheet-like EDG. Relevant ocular history, previous EDG treatments, MTX injection regimen, long-term outcomes and complications are reported. RESULTS: All cases were associated with intraocular surgery. Most patients were treated with 400 µm/0.1 mL MTX injections with a starting frequency of two times per week or weekly injections. Mean and SD number of injections per eye was 16±13 injections and duration of follow-up was 54±36 months (range: 7-120 months). Eradication of EDG was achieved in seven eyes of which one required a second MTX treatment course to achieve eradication, while clinical resolution with recurrence was observed in two. One treatment failure occurred despite eight weekly injections which slowed but did not halt EDG progression; the patient later requested that treatments be stopped given difficulty to come to follow-ups. Surface epitheliopathy developed in eight patients and was used to titrate MTX treatment. Six patients also developed endothelial failure. CONCLUSION: We report the largest case series of diffuse, sheet-like EDG treated with intraocular MTX with follow-ups up to 10 years. Intraocular MTX may be used effectively to achieve eradication of EDG in cases where surgery is not amenable. However, further recommendations to guide treatment remain warranted.
引用
- Hébert M, Kyrillos R, Snyder ME, et al. Intraocular methotrexate for epithelial downgrowth: long-term outcomes in a multicentre case series. Br J Ophthalmol. 2022. PMID: 35649694. doi:10.1136/bjophthalmol-2022-321168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。